EUVIMEDEUVIMED entdecken
Crossref

IL-9 Is a Biomarker of BIA-ALCL Detected Rapidly by Lateral Flow Assay

Peng Xu, Katerina Kourentzi, Richard Willson, Honghua Hu iD, Anand Deva, Patricia McGuire, Caroline Glicksman iD, Marshall Kadin

Aesthetic Surgery Journal · 2024

DOI: 10.1093/asj/sjae137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Surgery Journal, 2024. Verfasst von Peng Xu und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Interleukin-9, Lymphoma, Large-Cell, Anaplastic, Seroma, Breast Implants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Aesthetic Surgery Education and Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A delayed seroma around breast implants is the most common clinical presentation of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Interleukin-9 (IL-9), IL-10, and IL-13 concentrations are significantly higher in BIA-ALCL than in benign seromas, offering a means to distinguish between these conditions.

Objectives

The aim of this research was to test the ability of a lateral flow assay (LFA) to detect high concentrations of IL-9 rapidly. In addition, the authors compared CD30 and IL-9 LFAs for distinguishing BIA-ALCL from benign seromas.

Methods

Samples of 26 seromas (15 benign, 11 malignant) were tested on in-house-prepared LFA strips for IL-9 and CD30. Nanoparticle-conjugated antibodies specific to IL-9 and CD30 were used for detection. The intensity of both the test line (TL) and a control line (CL) were analyzed and the TL/CL ratio was calculated. IL-9 protein and IL-9 transcription factor PU.1 were stained in BIA-ALCL lines and clinical samples.

Results

The IL-9 LFA could reliably distinguish BIA-ALCL from benign seromas when the IL-9 concentration was >10 ng/ml. The CD30 LFA was positive in all 11 malignant cases. In 1 case with only faint CD30 and IL-10 TLs, the IL-9 LFA was clearly positive. Immunohistochemistry showed that IL-9 and PU.1 were present in tumor cells in BIA-ALCL lines and clinical samples.

Conclusions

Concentrations of IL-9 >10 ng/ml reliably distinguished BIA-ALCL from benign seromas. Moreover, the IL-9 LFA could detect BIA-ALCL when both the CD30 and IL-10 LFAs were not definitive, suggesting a multiplex LFA measuring IL-9, CD30, and IL-10 might be more effective in detecting BIA-ALCL in selected cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-9Lymphoma, Large-Cell, AnaplasticSeromaBreast ImplantsBiomarkers, TumorKi-1 AntigenHumansFemaleMiddle AgedAdultAgedBreast NeoplasmsBreast ImplantationDiagnosis, DifferentialPredictive Value of Tests

Substanzen

Interleukin-9Biomarkers, TumorKi-1 AntigenIL9 protein, human

Autor:innen und Institutionen

ORCID-Profile: Honghua Hu, Caroline Glicksman

Förderung

  • Aesthetic Surgery Education and Research Foundation

Zitieren

APA

Xu, P., Kourentzi, K., Willson, R., Hu, H., Deva, A., McGuire, P., Glicksman, C., & Kadin, M. (2024). IL-9 Is a Biomarker of BIA-ALCL Detected Rapidly by Lateral Flow Assay. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjae137

Vancouver

Xu P, Kourentzi K, Willson R, Hu H, Deva A, McGuire P, et al. IL-9 Is a Biomarker of BIA-ALCL Detected Rapidly by Lateral Flow Assay. Aesthetic Surgery Journal. 2024. doi:10.1093/asj/sjae137

BibTeX
@article{Xu2024,
  author = {Xu, Peng and Kourentzi, Katerina and Willson, Richard and Hu, Honghua and Deva, Anand and McGuire, Patricia and Glicksman, Caroline and Kadin, Marshall},
  title = {IL-9 Is a Biomarker of BIA-ALCL Detected Rapidly by Lateral Flow Assay},
  journal = {Aesthetic Surgery Journal},
  year = {2024},
  doi = {10.1093/asj/sjae137}
}
Kostenlos starten →